Answers are grounded in this paper and cite their sources.
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in HTT. Despite its well-defined genetic cause, developing safe and effective disease-modifying therapies has remained challenging. By September 2026, the therapeutic landscape included regulatory submissions for the adeno-associated virus serotype 5 (AAV5)-delivered RNA interference therapy ifezuntirgene inilparvovec (AMT-130) and the discontinuation of tominersen after the GENERATION HD2 trial, in which target engagement and biomarker responses were achieved without clinical benefit. These contrasting developments highlight both the progress achieved and the challenges of translating molecular interventions into clinical benefit. Here, we review five complementary therapeutic strategies grounded in current understanding of HD pathogenesis: editing the HTT sequence or modifying its epigenetic regulation; suppressing somatic CAG expansion by modulating DNA repair; lowering huntingtin expression with antisense oligonucleotides, AAV-delivered RNA interference and oral splicing modulators; modifying mutant huntingtin aggregation and proteostasis; and targeting downstream pathological processes. Together, these advances support combination approaches targeting multiple pathogenic mechanisms, although their efficacy and safety remain to be established. More than three decades after the identification of the causative mutation, a deeper understanding of HD biology and expanding therapeutic approaches provide grounds for cautious optimism about meaningful improvements for people with HD.
No takes yet. Share an insight, caveat, or question.
Ros et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: